Back to Search
Start Over
Phospholipase C[beta]3 in mouse and human dorsal root ganglia and spinal cord is a possible target for treatment of neuropathic pain
- Source :
- Proceedings of the National Academy of Sciences of the United States. Dec 16, 2008, Vol. 105 Issue 50, p20004, 5 p.
- Publication Year :
- 2008
-
Abstract
- Treatment of neuropathic pain is a major clinical problem. This study shows expression of phospholipase [beta]3 (PLC[beta]3) in mouse and human DRG neurons, mainly in small ones and mostly with a nonpeptidergic phenotype. After spared nerve injury, the pain threshold was strongly reduced, and systemic treatment of such animals with the unselective PLC inhibitor U73122 caused a rapid and long-lasting (48-h) increase in pain threshold. Thus, inhibition of PLC may provide a way to treat neuropathic pain. galanin receptor 2 | nerve injury | neuropeptide | pain treatment | sensory neuron
- Subjects :
- Peripheral nerve diseases -- Care and treatment
Ganglia -- Properties
Spinal cord -- Properties
Phospholipases -- Properties
Phospholipases -- Influence
Neuropeptides -- Properties
Neuropeptides -- Health aspects
Sensory receptors -- Properties
Sensory receptors -- Health aspects
Pain -- Care and treatment
Pain -- Research
Science and technology
Subjects
Details
- Language :
- English
- ISSN :
- 00278424
- Volume :
- 105
- Issue :
- 50
- Database :
- Gale General OneFile
- Journal :
- Proceedings of the National Academy of Sciences of the United States
- Publication Type :
- Academic Journal
- Accession number :
- edsgcl.191475285